Premium
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate
Author(s) -
Eskazan Ahmet Emre,
Ayer Mesut,
Kantarcioglu Bulent,
Arica Deniz,
Demirel Naciye,
Aydin Demet,
Yalniz Fevzi Firat,
Elverdi Tugrul,
Salihoglu Ayse,
Ar Muhlis Cem,
Ongoren Aydin Seniz,
Baslar Zafer,
Aydin Yildiz,
Tuzuner Nukhet,
Ozbek Ugur,
Soysal Teoman
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12937
Subject(s) - medicine , imatinib mesylate , reimbursement , tolerability , imatinib , adverse effect , myeloid leukemia , tyrosine kinase inhibitor , oncology , health care , cancer , economics , economic growth